Adalimumab (& biosimilars - Imraldi, Amgevita & Hyrimoz)

BNF:
10.1.3, 13.5.3, 1.5.3
Status:
Red
Decision Date:
March 2015
 

Comments

RED:

  • NICE TA373: for treating juvenile idiopathic arthritis (JIA).  NHSE commissioned.  (Decision date - January 2016)
  • NICE TA375: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
  • NICE TA383: for ankylosing spondylitis and non-radiographic axial spondyloarthritis.  (Decision date - March 2016)
  • NICE TA392: for treating moderate to severe hidradenitis suppurativa.  NHSE commissioned.  (Decision date - July 2016)
  • NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people.  NHSE commissioned.  (Decision date - August 2017)
  • NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis.  NHSE commissioned.  (Decision date - August 2017)
  • NICE TA715Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)

Adalimumab biosimilars include Imraldi, Hyrimoz & Amgevita.

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app